Khaddour K,Hana CK,Mewawalla P,Available P . .Treasure Island (FL): StatPearls Publishing; 2023 Jan-. [Updated 2023 May, 6 : .
Maedler-Kron C,Marcus VA,Michel RP .2016 .Hematopoietic stem cell transplantation. Pathology of Transplantation: A Practical Diagnostic Approach, : 401-49.
Barriga F,Ramírez P,Wietstruck A,Rojas N. .2012 .Hematopoietic stem cell transplantation: Clinical use and perspectives. Biol Res, 45(3) : 307-16.
Gyurkocza B,Sandmaier BM .2014 .Conditioning regimens for hematopoietic cell transplantation: One size does not fit all. Blood, 124(3) : 344-53.
Kang JS,Lee MH .2009 .Overview of therapeutic drug monitoring. Korean J Intern Med, 24(1) : 1-10.
Simeoli R,Dorlo TPC,Hanff LM,Huitema ADR,Dreesen E.,Editorial E. .2022 .: therapeutic drug monitoring (TDM): A useful tool for pediatric pharmacology applied to routine clinical practice. Front Pharmacol, 13 : 931843.
Gross AS .2001 .Best practice in therapeutic drug monitoring. Br J Clin Pharmacol, 52(Suppl 1) : 5S-10S.
Brunet M,van Gelder T,Åsberg A,Haufroid V,Hesselink DA,Langman L .2019 .Therapeutic drug monitoring of tacrolimuspersonalized therapy: Second consensus report. Ther Drug Monit, 41(3) : 261-307.
Kahan BD,Keown P,Levy GA,Johnston A .2002 .Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther, 24(3) : 330-50.
Dekkers BGJ,Bakker M,van der Elst KCM,Sturkenboom MGG,Veringa A,Span LFR .2016 .Therapeutic drug monitoring of posaconazole: An update. Curr Fungal Infect Rep, 10(2) : 51-61.
Slattery JT,Risler LJ .1998 .Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit, 20(5) : 543-9.
van der Stoep MYEC,Oostenbrink LVE,Bredius RGM,Moes DJAR,Guchelaar HJ,Zwaveling J .2022 .Therapeutic drug monitoring of conditioning agents in pediatric allogeneic stem cell transplantation; Where do we stand? Front Pharmacol. , 13 : 826004.
Menz BD,Stocker SL,Verougstraete N,Kocic D,Galettis P,Stove CP .2021 .Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br J Clin Pharmacol, 87(2) : 227-36.
Fang Z,Zhang H,Guo J,Guo J .2024 .Overview of therapeutic drug monitoring and clinical practice. Talanta, 266 : 124996.
Eliasson E,Lindh JD,Malmström RE,Beck O,Dahl ML .2013 .Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol, 69(1) : 25-32.
Bates DW .1998 .Improving the use of therapeutic drug monitoring. Ther Drug Monit, 20(5) : 550-5.
Salman B,Al-Khabori M .2021 .Applications and challenges in therapeutic drug monitoring of cancer treatment: A review. J Oncol Pharm Pract, 27(3) : 693-701.
Schuler U,Schroer S,Kühnle A,Blanz J,Mewes K,Kumbier I .1994 .Busulfan pharmacokinetics in bone marrow transplant patients: Is drug monitoring warranted? Bone Marrow Transplant. , 14(5) : 759-65.
Kletzel M,Jacobsohn D,Duerst R .2006 .Pharmacokinetics of a test dose of intravenous Busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous Busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 12(4) : 472-9.
Ruutu T,Eriksson B,Remes K,Juvonen E,Volin L,Remberger M .2002 .Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood, 100(6) : 1977-83.
Kitko CL,Gatwood K,Connelly J .2018 .Preparing the patient for HSCT: Conditioning regimens and their scientific rationale. Hematopoietic Stem Cell Transplantation for the Pediatric Hematologist/Oncologist, : 139-74.
Jethava Y,Sica S,Savani B,Socola F,Jagasia M,Mohty M .2017 .Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transplant, 52(11) : 1504-11.
Ciurea SO,Andersson BS .2009 .Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 15(5) : 523-36.
Fasslrinner F,Schetelig J,Burchert A,Kramer M,Trenschel R,Hegenbart U .2018 .Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: Retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol, 5(4) : e161-9.
Pasquini MC,Le-Rademacher J,Zhu X,Artz A,DiPersio J,Fernandez HF .2016 .Intravenous busulfan-based Myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant, 22(8) : 1424-30.
Storb R .2009 .Reduced-intensity conditioning transplantation in myeloid malignancies. Curr Opin Oncol, 21(Suppl 1) : S3-5.
Sharma A,Brooke RJ,Bhatt NS,Li Y,Allewelt HB,Bies JJ .2019 .Reduced intensity vs myeloablative conditioning regimen for pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia. Biol Blood Marrow Transplant, 25(3) : S14-S5.
Keusch F,Rao R,Chang L,Lepkowski J,Reddy P,Choi SW P .2014 .Participation in clinical research: Perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 20(10) : 1604-11.
Frangoul H,Najjar J,Simmons J,Domm J .2012 .Long-term follow-up and management guidelines in pediatric patients after allogenic hematopoietic stem cell transplantation. Semin Hematol, 49(1) : 94-103.
Tse WT,Duerst R,Schneiderman J,Chaudhury S,Jacobsohn D,Kletzel M .2009 .Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant, 44(3) : 145-56.
Salman B,Al-Za'abi M,Al-Huneini M,Dennison D,Al-Rawas A,AlKindi S .2017 .Therapeutic drug monitoring-guided dosing of busulfan differs from weight-based dosing in hematopoietic stem cell transplant patients. Hematol Oncol Stem Cell Ther, 10(2) : 70-8.
Gürlek Gökçebay D,Azik F,Ozbek N,Isik P,Avci Z,Tavil B .2015 .Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. Pediatr Transplant, 19(3) : 307-15.
Huezo-Diaz P,Uppugunduri CR,Tyagi AK,Krajinovic M,Ansari M. .2014 .Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children. Curr Drug Metab, 15(3) : 251-64.
Seydoux C,Battegay R,Halter J,Heim D,Rentsch KM,Passweg JR .2022 .Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 57(6) : 903-10.
Andersson BS,Madden T,Tran HT,Hu WW,Blume KG,Chow DSL .2000 .Acute safety and pharmacokinetics of intravenous Busulfan when used with oral Busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biol Blood Marrow Transplant, 6(5) : 548-54.
Madden T,de Lima M,Thapar N,Nguyen J,Roberson S,Couriel D .2007 .Pharmacokinetics of once-daily IV Busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant, 13(1) : 56-64.
Chen RL,Fang LH,Yang XY,El Amrani M,Uijtendaal EV,Chen YF .2021 .Therapeutic drug monitoring of Busulfan in patients undergoing hematopoietic cell transplantation: A pilot single-center study in Taiwan. , 14(7) : 613.
Russell JA,Kangarloo SB .2008 .Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des, 14(20) : 1936-49.
Bartelink IH,Boelens JJ,Bredius RG,Egberts AC,Wang C,Bierings MB .2012 .Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: Towards individualized dosing. Clin Pharmacokinet, 51(5) : 331-45.
Cremers S,Schoemaker R,Bredius R,den Hartigh J,Ball L,Twiss I .2002 .Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol, 53(4) : 386-9.
Abbasi N,Vadnais B,Knutson JA,Blough DK,Kelly EJ,O'Donnell PV .2011 .Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol, 51(10) : 1429-38.
Bartelink IH,Bredius RG,Belitser SV,Suttorp MM,Bierings M,Knibbe CA .2009 .Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant, 15(2) : 231-41.
Lawson R,Staatz CE,Fraser CJ,Hennig S. .2021 .Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients. Clin Pharmacokinet, 60(1) : 17-51.
Myers AL,Kawedia JD,Champlin RE,Kramer MA,Nieto Y,Ghose R .2017 .Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: A comprehensive review. Expert Opin Drug Metab Toxicol, 13(9) : 901-23.
.2015 .Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. Biol Blood Marrow Transplant, 21(8) : 1471-8.
McCune JS,Holmberg LA .2009 .Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol, 5(8) : 957-69.
Nath CE,Shaw PJ .2007 .Busulphan in blood and marrow transplantation: Dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol, 2(1) : 75-91.
Shao DF,Li JH,Hu T,Zhang ZX,Zhang L,Li JJ .2022 .Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring. Bone Marrow Transplant, 57(3) : 473-8.
Spinewine A,Byrne S,Dalleur O. .2023 .The role of pharmacists in optimising drug therapy. Optimizing Pharmacotherapy in Older Patients: An Interdisciplinary Approach, : 105-17.
Owusu-Obeng A,Weitzel KW,Hatton RC,Staley BJ,Ashton J,Cooper-Dehoff RM .2014 .Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy, 34(10) : 1102-12.